Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial
Kentaro Oka(Jichi Medical University), Daisuke Nagata(Jichi Medical University), Marina Miura, Yasuharu Miyazawa(Sapporo Minami Hospital), Takahiro Masuda(Jichi Medical University), Tetsu Akimoto(Jichi Medical University), Masato Morinari(Stony Brook School), Kazuyuki Shimada(Nagoya University), Ken Ohara(Jichi Medical University), Kyohei Misawa(Jichi Medical University)
Cited by 16
Related Papers
Morning Surge in Blood Pressure as a Predictor of Silent and Clinical Cerebrovascular Disease in Elderly Hypertensives
|Circulation|2003|1.2k
Stroke Prognosis and Abnormal Nocturnal Blood Pressure Falls in Older Hypertensives
|Hypertension|2001|750
Nocturnal Fall of Blood Pressure and Silent Cerebrovascular Damage in Elderly Hypertensive Patients
|Hypertension|1996|620
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
|American Journal of Physiology-Renal Physiology|2013|481
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
|American Journal of Physiology-Renal Physiology|2013|308